Wednesday, 07 December 2011 04:15

Norwich Soars With New Customers

Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing for the pharmaceutical and biotech industry, announced today that new business partnerships secured during the fourth quarter will generate significant revenue for the company.

Norwich has been expanding its development and pilot scale capabilities throughout 2011 in order to meet the growing market demand for comprehensive solutions that include scale-up and commercial manufacturing .

“Norwich is intensely focused to provide an experience for our customers that improves time efficiency and ensures quality,” said Terry Novak, president of Norwich Pharmaceuticals. “We continue to strategically invest in unique technical capabilities, and our strength with global distribution is being recognized as an advantage for several new customers.”

The new business partnerships announced today include five new projects that could add more than 500 million units to Norwich commercial production during the next three years with finished product being distributed in both the U.S. and Europe.

About Norwich Pharmaceuticals
Norwich is a full-service contract development and manufacturing provider for Rx and OTC pharmaceuticals. Norwich applies more than 120 years of experience and an unparalleled compliance record to offer customers greater flexibility, resources and speed that result in a streamlined progression from product development to scale-up and commercial manufacturing through clinical services. Visit www.norwichpharma.com for additional information.

 

Read 1534 times Last modified on Monday, 30 January 2012 10:20

Leave a comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.

Want more? Visit...

Videos

  • ICON- Partnerships 12
    ICON- Partnerships 12 Steven Cutler, Group President of ICON discusses the launch of ICON's new acquisition of Firecrest at Partnerships in Clinical Trials 2012. Facing the continuing challenge of not only monitoring and…
    Read more...
  • ICON- Partnerships 12
    ICON- Partnerships 12 Steven Cutler, Group President of ICON discusses their exciting new partnership with Roche at Partnerships In Clinical Trials 2012. Medical imaging has always been a strong department within ICON. ICON…
    Read more...
  • ERT- Partnerships 12
    ERT- Partnerships 12 John Blakely, Executive Vice President and Chief Commercial Officer for ERT discusses the new trend in clinical research at Partnerships in Clinical Trials 2012 - the melding of objective and…
    Read more...
  • Chiltern- Partnerships 12
    Chiltern- Partnerships 12 Marcelo Piccirillo, Senior Clinical Research Physician for Chiltern, discusses new trends in gastrointestinal clinical development at Partnerships in Clinical Trials 2012. Current hot spots for clinical development in the field…
    Read more...
  • Blinded Diagnostics - Partnerships 12
    Blinded Diagnostics - Partnerships 12 Paul Savuto, President and CFO, and Steven Karrupan, CEO, from Blinded Diagnostics discuss Point of Care Technology at Partnerships in Clinical Trials 2012. Point of care (or decentralized testing) offers…
    Read more...
  • American Airlines - IQPC 2011
    American Airlines - IQPC 2011 American Airlines has globally launched a passive solutions that gives a new alternative to pharmaceutical manufacturers.
    Read more...

Podcasts